ZebiAI, TB Alliance collaborate on tuberculosis targets

By The Science Advisory Board staff writers

February 2, 2021 -- Biotech firm ZebiAI has announced a collaboration agreement with nonprofit TB Alliance to further the discovery, development, and delivery of tuberculosis drugs.

TB Alliance will provide funds for ZebiAI to develop small molecule probes against key tuberculosis targets. The nonprofit will also have the right to exercise options for further discovery work on each target with ZebiAI.

The partnership is part of ZebiAI's Chemome Initiative, which utilizes the company's proprietary machine-learning algorithms to drive compound discovery, characterize protein function, and validate novel therapeutic targets.


Copyright © 2021 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.